Abstract
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative salvage treatment for patients with lymphoproliferative disorders (LPDs). In the United States, it is estimated that about 19,790 patients with non-Hodgkin lymphoma (NHL) and 1150 patients with Hodgkin lymphoma died in the calendar year of 2015. Progressive disease is a leading cause of mortality in patients with lymphomas. Although allo-HCT appears to be an attractive treatment option for patients with advanced lymphomas, its widespread application is often limited by factors such as HLA-matched donor availability and the risk of post-transplant morbidity. Haploidentical HCT (haplo-HCT) expands the allo-HCT strategy to patients without an available fully HLA-matched adult donor, while novel haplo-HCT techniques have improved the safety of this approach. Historically, in the haploidentical setting, severe graft-versus-host disease (GvHD), higher risk of non-relapse mortality (NRM), disease relapse, and delayed immune reconstitution were challenges despite extensive in vivo or ex vivo T-cell depletion aimed at reduced graft rejection and GvHD risk. More recently, several Asian centers have reported favorable outcomes of haplo-HCT utilizing T-cell replete grafts with intensive immunosuppression using antithymocyte globulin (ATG). A different strategy of T-cell replete haplo-HCT being increasingly used involves the administration of high-dose post-transplantation cyclophosphamide (PTCy), which mitigates the risk of GvHD by targeting alloreactive T-cells rapidly proliferating early after HLA-mismatched transplant while sparing regulatory T-cells and hematopoietic progenitor cells. The near universal and ease of haploidentical donor availability have led to a rapid adoption of this strategy in patients with LPDs.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
National Cancer Institute. SEER stat fact sheet: Hodgkin’s lymphoma. http://seer.cancer.gov/statfacts/html/hodg.html. Accessed 2016.
National Cancer Institute. SEER stat fact sheet: non-Hodgkin’s lymphoma. http://seer.cancer.gov/statfacts/html/nhl.html. Accessed 2016.
Favier O, Heutte N, Stamatoullas-Bastard A, et al. Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer. 2009;115(8):1680–91.
Reisner Y, Aversa F, Martelli MF. Haploidentical hematopoietic stem cell transplantation: state of art. Bone Marrow Transplant. 2015;50(Suppl 2):S1–5.
Fuchs EJ. Haploidentical transplantation for hematologic malignancies: where do we stand? Hematology Am Soc Hematol Educ Program. 2012;2012:230–6.
Wang Y, Liu DH, Liu KY, et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer. 2013;119(5):978–85.
Fuchs EJ. HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide. Bone Marrow Transplant. 2015;50(Suppl 2):S31–6.
Hamadani M, Craig M, Awan FT, Devine SM. How we approach patient evaluation for hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010;45(8):1259–68.
Raiola A, Dominietto A, Varaldo R, et al. Unmanipulated haploidentical BMT following nonmyeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma. Bone Marrow Transplant. 2014;49(2):190–4.
Kanakry JA, Kasamon YL, Gocke CD, et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant. 2013;19(4):602–6.
Kasamon YL, Bolaños-Meade J, Prince GT, et al. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J ClinOncol. 2015;33(28):3152–61.
Farina L, Bruno B, Patriarca F, et al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or nonmyeloablative allogeneic stem cell transplantation. Leukemia. 2009;23(6):1131–8.
Chang YJ, Luznik L, Fuchs EJ, Huang XJ. How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation? J Hematol Oncol. 2016;9:35.
Wang Y, Chang YJ, LP X, et al. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood. 2014;124(6):843–50.
Ciurea SO, Champlin RE. Donor selection in T cell-replete haploidentical hematopoietic stem cell transplantation: knowns, unknowns, and controversies. Biol Blood Marrow Transplant. 2013;19(2):180–4.
Bashey A, Zhang X, Jackson K, et al. Comparison of outcomes of hematopoietic cell transplants from t-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and HLA-identical sibling donors: a multivariable analysis including disease risk index. Biol Blood Marrow Transplant. 2016;22(1):125–33.
Brammer JE, Khouri I, Gaballa S, et al. Outcomes of haploidentical stem cell transplantation for lymphoma with melphalan-based conditioning. Biol Blood Marrow Transplant. 2016;22(3):493–8.
Hamadani M, Saber W, Ahn KW, et al. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant. 2013;19(5):746–53.
Hamadani M, Saber W, Ahn KW, et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2013;19(4):625–31.
Fenske TS, Ahn KW, Graff TM, et al. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol. 2016;174(2):235–48. https://doi.org/10.1111/bjh.14046.
Bacher U, Klyuchnikov E, Le-Rademacher J, et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood. 2012;120(20):4256–62.
McCurdy SR, Kanakry JA, Showel MM, et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose post transplantation cyclophosphamide. Blood. 2015;125(19):3024–31.
Kanakry JA, Gocke CD, Bolaños-Meade J, et al. Phase II study of nonmyeloablative allogeneic bone marrow transplantation for B cell lymphoma with post-transplantation rituximab and donor selection based first on non-HLA factors. Biol Blood Marrow Transplant. 2015;21(12):2115–22.
Kanate AS, Mussetti A, Kharfan-Dabaja MA, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127(7):938–47.
Burroughs LM, O'Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(11):1279–87.
Karmali R, Ghosh N, Rocha G, et al. Survival after T-cell replete haploidentical related donor hematopoietic cell transplantation (Haplo-HCT) using post-transplant cyclophosphamide (PT-CY) compared with HLA-matched related donor (MRD) transplant for lymphomas. Biol Blood Marrow Transplant. 2016;22(3):S75–6.
Dietrich S, Finel H, Martinez C, et al. Haplotransplants versus other alternative donors for allogeneic stem cell transplantation in non Hodgkin lymphoma (NHL): a retrospective analysis of the EBMT Lymphoma Working Party. ASH 2014 annual meeting abstract. Blood. 2014;124:2573.
Martinez C, Gayoso J, Canals C, et al. Alternative donors (umbilical cord blood and haploidentical donors) for allogeneic stem cell transplantation in relapsed/refractory hodgkin lymphoma: a retrospective analysis of the EBMT Lymphoma Working Party and the Spanish Group of Stem Cell Transplantation (GETH). ASH 2015 annual meeting abstract. Blood. 2015;126:4399.
Castagna L, Bramanti S, Furst S, et al. Nonmyeloablative conditioning, unmanipulatedhaploidentical SCT and post-infusion CY for advanced lymphomas. Bone Marrow Transplant. 2014;49(12):1475–80.
Zeidan AM, Forde PM, Symons H, et al. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2014;20(3):314–8.
Huang XJ. Immunomodulatory strategies for relapse after haploidentical hematopoietic stem cell transplantation in hematologic malignancy patients. Best Pract Res Clin Haematol. 2011;24(3):351–8.
Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–50.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Murthy, G.S.G., Hamadani, M., Hari, P.N. (2018). Haploidentical Hematopoietic Cell Transplantation in Lymphomas. In: Ciurea, S., Handgretinger, R. (eds) Haploidentical Transplantation. Advances and Controversies in Hematopoietic Transplantation and Cell Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-54310-9_16
Download citation
DOI: https://doi.org/10.1007/978-3-319-54310-9_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-54309-3
Online ISBN: 978-3-319-54310-9
eBook Packages: MedicineMedicine (R0)